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CD34 CELLS PURIFIED AUTOLOGOUS PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION FOR THE TREATMENT OF REFRACTORY AU-
TOIMMUNE DISEASES
Nagafuji, K., Miyamoto, T., Fukuda, T., Tsukamoto, H., Horiuchi, T.,
Harada, M. First Department of Internal Medicine, Kyushu University
Hospital, Fukuoa, Japan.
The aim of this study was to evaluate the safety and efﬁcacy of
CD34 cells in autologous peripheral blood stem cell transplan-
tation (PBSCT) for the treatment of refractory autoimmune dis-
eases (AD). Methods: Six cases of systemic sclerosis (SSc) with
interstitial pneumonia (IP), one case of amyopathic dermatomyo-
sitis (ADM) with IP, and one case of Wegener’s granulomatosis
with exophthalmous. PBSCs were mobilized with CY 4 g/m2 
G-CSF, and CD34 cells were puriﬁed with CliniMACS. Pre-
transplantation conditioning consisted of CY 200 mg/kg. Result:
There was no treatment-related mortality. Hematologic recoveries
after PBSCT of six patients with SSc were neutrophils  500 on
days 9–11 and platelets  5  104 days 10–20. Improvements in
skin scores and PaO2 were observed. The patient with ADM/IP
enjoyed dramatic improvement of her IP lasting more than 18
months. Five of eight patients became positive for cytomegalovirus
antigenemia, which was successfully treated with gancyclovir or
foscarnet. Two of eight patients developed adenoviral hemorrhagic
cystitis, which was successfully treated with cidofovir.Conclusion:
This treatment could be done with acceptable toxicity, resulting in
signiﬁcant improvement of AD.
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RECOVERY FROM AND CONSEQUENCES OF SEVERE IATROGENIC LYM-
PHOPENIA (INDUCED TO TREAT AUTOIMMUNE DISEASES)
Storek, J., Zhao, Z., McSweeney, P.A., Nash, R.A., Akatsuka, Y.,
Sullivan, K.M., Maloney, D.G. Fred Hutchinson Cancer Research Cen-
ter and University of Washington, Seattle, WA.
To ascertain the consequences of severe leukopenia and the
tempo of recovery, we studied the immunity of 56 adult patients
treated for multiple sclerosis or systemic sclerosis with autologous
CD34 cell transplantation using extremely lymphoablative condi-
tioning. Results: NK cell, monocyte, and neutrophil counts re-
covered to normal by 1 month, dendritic cell and B cell counts by
6 months and T cell counts by 2 years posttransplantation, al-
though CD4 T cell counts remained borderline low. Initial pe-
ripheral expansion was robust for CD8 T cells but only moderate
for CD4 T cells. Subsequent thymopoiesis was slow, especially in
older patients. Importantly, levels of antibodies, including autoan-
tibodies, did not drop substantially. Infections were frequent dur-
ing the ﬁrst 6 months, when all immune cells were deﬁcient, and
surprisingly rare (0.21 per patient year) at 7–24 months posttrans-
plantation, when only T cells (particularly CD4 T cells) were
deﬁcient. Conclusion: Peripheral expansion of CD8 but not CD4
T cells is highly efﬁcient. Prolonged CD4 lymphopenia is associ-
ated with relatively few infections, possibly due to antibodies pro-
duced by persisting pretransplantation plasma cells. The clinical
relevance of the persistence of autoantibodies needs to be studied.
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TREATMENT OF POSTTRANSPLANTATION DIABETES MELLITUS WITH
ANTI-CD20 MONOCLONAL ANTIBODIES
Vandenbosch, K., Champagne, M.A., Gonthier, M., Moghrabi, A.,
Vachon, M.-F., Duval, M. Sainte-Justine Hospital, Montreal, Quebec,
Canada.
Anti-CD20 has been successfully used for the treatment of im-
mune manifestations after HSCT. We report the use of this treat-
ment for post-HSCT diabetes mellitus. An 11-year-old boy re-
ceived a HSCT from an HLA-identical sibling for AML CR1.
Preparative regimen consisted of fractioned TBI and etoposide,
along with graft-versus-host prophylaxis of cyclosporin and meth-
otrexate. SCT resulted in full donor engraftment. Cyclosporin was
discontinued on day 28 posttransplantation due to renal failure.
Subsequently, acute grade III skin GVHD was successfully treated
with glucocorticoids, with no glucose intolerance. Glucocorticoids
were discontinued at 5 months posttransplantation. At that time,
buccal lichen planus was present. No speciﬁc treatment was given.
At 12 months posttransplantation, the patient developed bronchi-
olitis obliterans and vitiligo (face, arms, and hips). Prednisone (up
to 1 mg/kg/day) was resumed; pulmonary function improved, but
skin lesions persisted unchanged. Again, glucocorticoid therapy did
not induce glucose intolerance. At 22 months posttransplantation,
glucocorticoids were tapered and azathioprine and hydroxychloro-
quine begun. Mofetylmycofenolate was substituted for azathio-
prine at 28 months posttransplantation. At 31 months posttrans-
plantation, the patient discontinued all treatment, including
glucocorticoids. His condition remained stable thereafter until he
developed hypothyroidism at 69 months posttransplantation,
treated with L-thyroxine. Antimicrosomal and antithyroglobulin
antibodies were negative. At 81 months posstransplantation, the
patient experienced polyuria, polydipsia, and major weight loss.
Hos blood sugar level was 36 mmol/l (648 mg/dl). He had keto-
nuria but no ketoacidosis. His HbA1c level was 13.4% (normal,
4.8% to 6.0%). The diagnosis of diabetes mellitus was made.
Diabetes was controlled with insulin, 1.1 U/kg/day. Tests for
associated autoantibodies were all negative, including anti–glu-
tamic acid decarboxylase (GAD) antibodies. There was no history
of diabetes mellitus in the donor or in the more extended family.
The patient’s body mass index was in the 72nd percentile. Four
doses of weekly intravenous (IV) rituximab(375 mg/m2/dose) were
administered, followed by monthly IV gammaglobulins. Insulin
was discontinued 3 months after the last dose of rituximab therapy.
Four months later, the patient remains free of symptoms and
normoglycemic, with an HbA1c level of 6,1%. Although the pa-
tient may be experiencing a “honeymoon” phenomenon with spon-
taneous, transitory remission of diabetes, our experience could also
suggest that diabetes mellitus developing after SCT may be of
immune origin, and that early treatment with anti-CD20 might
modify the course of the disease.
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INTENSIVE IMMUNOSUPPRESSION AND TRANSPLANTATION OF T-CELL
DEPLETED AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PA-
TIENTS WITH SYSTEMIC SCLEROSIS: AN ONGOING PHASE I TRIAL
BuchBarker, D.1, Donnenberg, A.D.1, Medsger, T.A.2, Carroll, M.P.1,
Grifﬁn, D.L.1, Blair, C.2, Lis, D.1, Yeager, A.M.1 1University of
Pittsburgh Cancer Institute, Pittsburgh, PA; 2Division of Rheumatology,
Department of Medicine, University of Pittsburgh School of Medicine,
Pittsburgh, PA.
In patients who undergo autologous peripheral blood stem cell
transplantation (PBSCT) for severe autoimmune disorders, a pre-
parative regimen that optimizes immunosuppression without ex-
cessive myelotoxicity would potentially have favorable safety and
efﬁcacy proﬁles. We are conducting a phase I trial of cyclophos-
phamide (CY) dose escalation (initial dose 200 mg/m2/day  5,
days 7 to 3) plus ﬂudarabine (25 mg/m2/day  5, days 7 to
3) and rabbit anti-thymocyte globulin (ATG) (thymoglobulin;
2.5 mg/kg/day  3, days 5 to 3) followed by T-cell–depleted
(TCD) autologous PBSCT in adults with systemic sclerosis (SSc).
To date, 5 patients (median age, 44 years; range, 39–59 years) have
been treated on this study. Each patient had satisfactory PBSC
collection with one 4-hour large-volume leukapheresis after mo-
bilization with CY (2000 mg/m2) plus G-CSF. To deplete T cells
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